Search results for "asthma"

showing 10 items of 860 documents

Impact of extrafine formulations of inhaled corticosteroids/long-acting beta-2 agonist combinations on patient-related outcomes in asthma and COPD

2014

Nicola Scichilone,1 Alida Benfante,1 Luca Morandi,2 Federico Bellini,2 Alberto Papi21Biomedical Department of Internal and Specialist Medicine, Section of Pulmonology, University of Palermo, Italy; 2Respiratory Medicine, Department of Medical Sciences, University of Ferrara, Ferrara, ItalyAbstract: Asthma and chronic obstructive pulmonary disease (COPD) are among the most common chronic diseases worldwide, characterized by a condition of variable degree of airway obstruction and chronic airway inflammation. A large body of evidence has demonstrated the importance of small airways as a pharmacological target in these clinical conditions. Despite a deeper understanding of the pathophysiologic…

Agonistmedicine.medical_specialtymedicine.drug_classReviewPharmacologySettore MED/10 - Malattie Dell'Apparato RespiratorioInternal medicineinhalational therapymedicineCOPDRespiratory systemAsthmaCOPDlcsh:R5-920small airwaysCOPD asthma inhalational therapy small airwaysLungbusiness.industryrespiratory systemAirway obstructionasthmamedicine.diseasePathophysiologyrespiratory tract diseasesmedicine.anatomical_structureFormoterolbusinesslcsh:Medicine (General)medicine.drug
researchProduct

Perturbation of metabolic pathways mediates the association of air pollutants with asthma and cardiovascular diseases.

2018

Background: Epidemiologic evidence indicates common risk factors, including air pollution exposure, for respiratory and cardiovascular diseases, suggesting the involvement of common altered molecular pathways. Objectives: The goal was to find intermediate metabolites or metabolic pathways that could be associated with both air pollutants and health outcomes (“meeting-in-the-middle”), thus shedding light on mechanisms and reinforcing causality. Methods: We applied a statistical approach named ‘meet-in-the-middle’ to untargeted metabolomics in two independent case-control studies nested in cohorts on adult-onset asthma (AOA) and cardio-cerebrovascular diseases (CCVD). We compared the results …

Air pollution Untargeted metabolomics Metabolic pathways Adult-onset asthma Cardio-cerebrovascular diseases0301 basic medicineChronic exposureAdultAir pollution exposureAir pollutionAir pollution010501 environmental sciencesmedicine.disease_cause01 natural sciencesSettore MED/01 - Statistica Medica03 medical and health sciencesAir pollutantsMD MultidisciplinarymedicineHumans0105 earth and related environmental sciencesGeneral Environmental ScienceAsthmaCardio-cerebrovascular diseasesAir PollutantsUntargeted metabolomicsOdds ratioEnvironmental Exposuremedicine.diseaseAsthmaMetabolic pathway030104 developmental biologyUntargeted metabolomicsMetabolic pathwaysCardiovascular DiseasesCase-Control StudiesImmunologyEXPOsOMICS ConsortiumEnvironmental SciencesMetabolic Networks and PathwaysAdult-onset asthmaEnvironment international
researchProduct

Airway Wall Thickness By HRCT Does Not Affect Airway Distensibility In Asthma And COPD

2013

Airways HRCT ASTHMA COPDSettore MED/10 - Malattie Dell'Apparato Respiratorio
researchProduct

Current therapeutical strategies for allergic rhinitis

2018

Allergic rhinitis is a common condition with increasing prevalence and is associated with several comorbid disorders such as bronchial asthma and atopic dermatitis. If allergen avoidance is not possible, allergen-specific immunotherapy is the only causal treatment option.This review focuses on current treatments and the future outlook for allergic rhinitis. Pharmacotherapy includes mast cell stabilizers, antihistamines, glucocorticosteroids (GCSs), leukotriene receptor antagonists, and nasal decongestants. Nasal GCSs are currently regarded as the most effective treatment and are considered first-line therapy together with non-sedating antihistamines. The new formulation MP29-02 combines the…

Allergen immunotherapyRhinitis allergicTreatment outcomeHistamine Antagonistsmacromolecular substancesmedicine.disease_cause03 medical and health sciences0302 clinical medicineAllergenimmune system diseasesmedicineHumansPharmacology (medical)AsthmaPharmacologybusiness.industryHistamine antagonistsGeneral MedicineAtopic dermatitisrespiratory systemmedicine.diseaseRhinitis Allergicrespiratory tract diseasesbody regionsTreatment OutcomeDesensitization Immunologic030220 oncology & carcinogenesisImmunologybusiness030217 neurology & neurosurgeryExpert Opinion on Pharmacotherapy
researchProduct

Efficacy and safety of allergen immunotherapy in patients with allergy to molds: A systematic review

2018

BACKGROUND Allergen immunotherapy (AIT) with mould extracts has been performed for many years but the final demonstration of its clinical efficacy is still missing, due to the small number of studies and their inconsistent results. OBJECTIVE To systematically review efficacy and safety of AIT for the treatment of respiratory allergies to moulds. DESIGN The primary outcomes were safety and reduction of symptoms (Symptom Score, SS) and medication use (Medication Score, MS) in patients treated with AIT compared to controls. The strength of the evidence was graded based on the risk of bias, consistency and magnitude of effect, according to the GRADE Working Group's guide. DATA SOURCES Medline, …

Allergen immunotherapymedicine.medical_specialtyAllergyAntigens FungalImmunologyMEDLINECochrane LibraryPlacebo03 medical and health sciences0302 clinical medicinePharmacotherapyInternal medicineHypersensitivityHumansImmunology and AllergyMedicineAnti-Asthmatic Agents030212 general & internal medicineAsthmaClinical Trials as Topicbusiness.industryFungiAllergensmedicine.diseasePhenotypeTreatment Outcome030228 respiratory systemDesensitization ImmunologicSample size determinationbusinessClinical & Experimental Allergy
researchProduct

Technical standards in allergen exposure chambers worldwide - an EAACI Task Force Report

2021

Allergen exposure chambers (AECs) can be used for controlled exposure to allergenic and non-allergenic airborne particles in an enclosed environment, in order to (i) characterize the pathological features of respiratory diseases and (ii) contribute to and accelerate the clinical development of pharmacological treatments and allergen immunotherapy for allergic disease of the respiratory tract (such as allergic rhinitis, allergic rhinoconjunctivitis, and allergic asthma). In the guidelines of the European Medicines Agency for the clinical development of products for allergen immunotherapy (AIT), the role of AECs in determining primary endpoints in dose-finding Phase II trials is emphasized. A…

Allergen immunotherapymedicine.medical_specialtyAllergyImmunologytechnical standardsmedicineImmunology and AllergyHumansallergen exposure chambersIntensive care medicineCOVID-19 ; allergen exposure chambers ; clinical trials ; Allergie ; technical standards ; allergen immunotherapyField exposureclinical trialsTask forcebusiness.industryCOVID-19Technical informationAllergic asthmaAllergensrespiratory systemmedicine.diseaseRhinitis AllergicAsthmaClinical trialDesensitization Immunologicallergen immunotherapyPollenALLERGEN EXPOSUREbusiness
researchProduct

The effect of allergen immunotherapy in the onset of new sensitizations: a meta-analysis

2017

Background Although the preventive efficacy of allergen immunotherapy (AIT) in the onset of new allergen sensitizations has been asserted by many reviews, position papers, and consensus conferences, the evidence available is from only 3 studies. The objective of this work was a systematic review to evaluate the preventive efficacy of AIT in the onset of new allergen sensitizations. The end-point was the risk difference (RD) in the onset of new allergen sensitizations between patients treated with AIT and pharmacotherapy. Methods Computerized bibliographic searches of MEDLINE, EMBASE, and the Cochrane Library (until November 30th, 2016) were done. Random-effects and fixed-effects model meta-…

Allergen immunotherapymedicine.medical_specialtybusiness.industryCochrane Librarymedicine.diseasemedicine.disease_causelaw.invention03 medical and health sciences0302 clinical medicineAllergenPharmacotherapy030228 respiratory systemOtorhinolaryngologyRandomized controlled triallawMeta-analysisInternal medicinemedicineImmunology and AllergyObservational study030212 general & internal medicinebusinessAsthmaInternational Forum of Allergy & Rhinology
researchProduct

Manifesto on small airway involvement and management in asthma and chronic obstructive pulmonary disease: an Interasma (Global Asthma Association - G…

2016

International audience; Evidence that enables us to identify, assess, and access the small airways in asthma and chronic obstructive pulmonary disease (COPD) has led INTERASMA (Global Asthma Association) and WAO to take a position on the role of the small airways in these diseases. Starting from an extensive literature review, both organizations developed, discussed, and approved the manifesto, which was subsequently approved and endorsed by the chairs of ARIA and GA2LEN. The manifesto describes the evidence gathered to date and defines and proposes issues on small airway involvement and management in asthma and COPD with the aim of challenging assumptions, fostering commitment, and bringin…

Allergic Rhinitislcsh:Immunologic diseases. AllergyPulmonary and Respiratory MedicineManifestomedicine.medical_specialtyAllergyChronic Obstructive Pulmonary DiseaseImmunologyMEDLINEDiseaseSettore MED/10 - Malattie Dell'Apparato Respiratoriosmall airways asthma aerosolBiochemistry03 medical and health sciences0302 clinical medicine[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathology/dk/atira/pure/subjectarea/asjc/2700/2723Position Article and GuidelinesmedicineImmunology and Allergy030212 general & internal medicinesmall airwayIntensive care medicineAsthmaCOPDLungbusiness.industryasthma airway inflammationOrganic Chemistrysmall airways asthma control aerosol1103 Clinical SciencesChronic Obstructive Pulmonary Disease Patientasthmarespiratory systemmedicine.diseaserespiratory tract diseasesmedicine.anatomical_structure030228 respiratory systemPhysical therapylcsh:RC581-607AirwaybusinesscontrolThe World Allergy Organization Journal
researchProduct

Interruption of CD28-mediated costimulation during allergen challenge protects mice from allergic airway disease

2012

Background Allergic asthma is a T H 2-promoted hyperreactivity with an immediate, IgE, and mast cell–dependent response followed by eosinophil-dominated inflammation and airway obstruction. Objective Because costimulation by CD28 is essential for T H 2 but not T H 1 responses, we investigated the effect of selective interference with this pathway in mice using the models of ovalbumin and house dust mite–induced airway inflammation. Methods To study the role of CD28 in the effector phase of allergic airway inflammation, we developed an inducibly CD28-deleting mouse strain or alternatively used a CD28 ligand-binding site–specific mouse anti-mouse mAb blocking CD28 engagement. Results We show …

Allergic asthmaLymphocyte ActivationImmunoglobulin Emedicine.disease_causeT-Lymphocytes RegulatoryMice0302 clinical medicineAirway resistanceAllergenImmunology and AllergySensitizationMice Inbred BALB C0303 health sciencesbiologyAntibodies Monoclonalovalbuminrespiratory system3. Good healthmedicine.anatomical_structurecostimulationconditional CD28 knockout miceFemalemedicine.symptomImmunologyInflammation03 medical and health sciencesTh2 CellsCD28 AntigensRespiratory HypersensitivitymedicineAnimalsHumansAntigens DermatophagoidesLymphocyte CountAntibodies Blocking030304 developmental biologyHouse dust miteCD28-specific mAbbusiness.industryReceptor Cross-TalkAirway obstructionmedicine.diseasebiology.organism_classificationMice Mutant Strainsrespiratory tract diseasesDisease Models AnimalCTLA-4Immunologybiology.proteinbusiness030215 immunology
researchProduct

SLIT's Prevention of the Allergic March.

2018

PURPOSE OF REVIEW: The progression of atopic disorders from atopic dermatitis in infants to allergic rhinitis and asthma in children, adolescents, and adults defines the allergy march. Allergen immunotherapy is the only causal treatment altering the immunological mechanism underlying the allergic diseases. The sublingual administration route is more acceptable than the subcutaneous one in pediatric age. RECENT FINDINGS: Several studies show the efficacy and safety profile of sublingual immunotherapy (SLIT) for the treatment of respiratory allergy diseases, but few data are available on its effect of primary and secondary prevention of allergic disease. The purpose of this manuscript is to r…

Allergic march0301 basic medicinePulmonary and Respiratory MedicineAllergen immunotherapymedicine.medical_specialtyAllergyImmunologyDiseaseSublingual administration03 medical and health sciences0302 clinical medicineAllergen immunotherapy; Allergic march; Primary prevention; Secondary prevention; Sublingual immunotherapy; Immunology and Allergy; Immunology; Pulmonary and Respiratory MedicinemedicineHypersensitivityImmunology and AllergyHumansAllergen immunotherapyAsthmaSecondary preventionSublingual ImmunotherapyPrimary preventionbusiness.industrySecondary preventionAtopic dermatitismedicine.diseaseDermatologySlit030104 developmental biology030228 respiratory systembusinessCurrent allergy and asthma reports
researchProduct